Conteltinib

康太替尼

Report date: 2025/02/17 15:43:00
NME

Base Information

Drug NameConteltinib
Drug Alias Name首要泽CT-707SY-707
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFocal adhesion kinase 1 inhibitorsFocal adhesion kinase 2 inhibitorsAnaplastic lymphoma kinase inhibitors +[4] 
TargetsInsulin-like growth factor I receptorAnaplastic lymphoma kinaseFocal adhesion kinase 1 +[4] 
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesBeijing Centaurus Biopharma Co LtdShouyao Holding (Beijing) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeijing Sl Pharmaceutical Co LtdPharmablock Sciences (Nanjing) IncShouyao Holding (Beijing) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A